EUVIMEDEUVIMED entdecken
Crossref

Prognosis After Discontinuation of Azathioprine or Mycophenolate Mofetil in Well‐Controlled Myasthenia Gravis: A Retrospective Analysis

Inci Sule Ozer iD, Ergi Kaya iD, Ahmet Yusuf Ertürk iD, Ihsan Sukru Sengun iD

Muscle & Nerve · 2026

DOI: 10.1002/mus.70105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Muscle & Nerve, 2026. Verfasst von Inci Sule Ozer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Dokuz Eylul University Medical School, Izmir, Turkey. Hauptthemen laut MEDLINE: Myasthenia Gravis, Azathioprine, Mycophenolic Acid, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Azathioprine (AZA) and mycophenolate mofetil (MMF) are generally used for long periods when treating myasthenia gravis. In well‐controlled patients, discontinuation of AZA/MMF may be a cause for concern because of the possibility of relapse. We aimed to evaluate relapse and relapse‐related parameters after discontinuation of AZA/MMF.

Method

Patients who had discontinued AZA or MMF monotherapy were retrospectively reviewed. We reviewed relapse, whether in pharmacological remission (PR) or exhibiting minimal manifestations (MM 1), disease duration, duration of AZA/MMF use, and other clinical parameters.

Results

A total of 32 patients were included who either discontinued AZA ( n = 28) or MMF ( n = 4) treatments. Relapse was detected in 11 (34%). Patients in PR had fewer relapses than those with MM 1 ( p = 0.023). Intravenous immunoglobulin was required in four. All patients who relapsed were stabilized with AZA/MMF. No significant association was found between relapse and age of disease onset, duration of disease, duration of AZA/MMF use, thymectomy status, or maximum Myasthenia Gravis Foundation of America score during active disease.

Discussion

The results of this study suggest that patients in PR are less likely to relapse compared to those in MM 1. In well‐controlled MG patients, AZA/MMF may be discontinued.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myasthenia GravisAzathioprineMycophenolic AcidImmunosuppressive AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedAdultAgedPrognosisRecurrenceYoung Adult

Stichwörter der Autor:innen

azathioprinediscontinuation of AZA/MMFimmune suppressive treatmentmyasthenia gravismycophenolate mofetil

Substanzen

AzathioprineMycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Neurology, Dokuz Eylul University Medical School, Izmir, Turkey.

ORCID-Profile: Inci Sule Ozer, Ergi Kaya, Ahmet Yusuf Ertürk, Ihsan Sukru Sengun

Zitieren

APA

Ozer, I. S., Kaya, E., Ertürk, A. Y., & Sengun, I. S. (2026). Prognosis After Discontinuation of Azathioprine or Mycophenolate Mofetil in Well‐Controlled Myasthenia Gravis: A Retrospective Analysis. Muscle & Nerve. https://doi.org/10.1002/mus.70105

Vancouver

Ozer IS, Kaya E, Ertürk AY, Sengun IS. Prognosis After Discontinuation of Azathioprine or Mycophenolate Mofetil in Well‐Controlled Myasthenia Gravis: A Retrospective Analysis. Muscle & Nerve. 2026. doi:10.1002/mus.70105

BibTeX
@article{Ozer2026,
  author = {Ozer, Inci Sule and Kaya, Ergi and Ertürk, Ahmet Yusuf and Sengun, Ihsan Sukru},
  title = {Prognosis After Discontinuation of Azathioprine or Mycophenolate Mofetil in Well‐Controlled Myasthenia Gravis: A Retrospective Analysis},
  journal = {Muscle & Nerve},
  year = {2026},
  doi = {10.1002/mus.70105}
}
Kostenlos starten →